[go: up one dir, main page]

BR9708460A - Composto, composição farmacêutica e processo para prevenir ou tratar uma condição patológica em um humano ou animal não-humano. - Google Patents

Composto, composição farmacêutica e processo para prevenir ou tratar uma condição patológica em um humano ou animal não-humano.

Info

Publication number
BR9708460A
BR9708460A BR9708460-3A BR9708460A BR9708460A BR 9708460 A BR9708460 A BR 9708460A BR 9708460 A BR9708460 A BR 9708460A BR 9708460 A BR9708460 A BR 9708460A
Authority
BR
Brazil
Prior art keywords
human
compound
pharmaceutical composition
pathological condition
treating
Prior art date
Application number
BR9708460-3A
Other languages
English (en)
Inventor
Raymond J Bergeron Jr
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of BR9708460A publication Critical patent/BR9708460A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/10—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA E PROCESSO PARA PREVENIR OU TRATAR UMA CONDIçãO PATOLóGICA EM UM HUMANO OU ANIMAL NãO-HUMANO". Os ácidos 2-(1-hidróxi aril)-tiazolino-4-carboxílicos e derivados são úteis como queladores de metais trivalentes, em aplicações terapêuticas.
BR9708460-3A 1996-03-29 1997-03-31 Composto, composição farmacêutica e processo para prevenir ou tratar uma condição patológica em um humano ou animal não-humano. BR9708460A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/624,289 US5840739A (en) 1992-11-16 1996-03-29 Thiazoline acid derivatives
PCT/US1997/004666 WO1997036885A1 (en) 1996-03-29 1997-03-31 Thiazoline acid derivatives

Publications (1)

Publication Number Publication Date
BR9708460A true BR9708460A (pt) 2000-01-04

Family

ID=24501405

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9708460-3A BR9708460A (pt) 1996-03-29 1997-03-31 Composto, composição farmacêutica e processo para prevenir ou tratar uma condição patológica em um humano ou animal não-humano.

Country Status (13)

Country Link
US (1) US5840739A (pt)
EP (3) EP0900209A4 (pt)
JP (2) JP3800559B2 (pt)
KR (1) KR20000005100A (pt)
AT (1) ATE449088T1 (pt)
AU (1) AU715889B2 (pt)
BR (1) BR9708460A (pt)
CA (1) CA2250243C (pt)
DE (1) DE69739670D1 (pt)
NO (1) NO315608B1 (pt)
NZ (2) NZ509967A (pt)
PL (1) PL329172A1 (pt)
WO (1) WO1997036885A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
WO1999039706A1 (en) 1998-02-04 1999-08-12 University Of Florida Research Foundation, Inc. Pharmaceuticals comprising n,n'-bis(2- hydroxybenzyl) ethylenediamine-n, n'-diacetic acid for iron chelating therapy
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
US6323218B1 (en) 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6083966A (en) * 1998-08-31 2000-07-04 University Of Florida Thiazoline acid derivatives
US6159983A (en) * 1998-09-18 2000-12-12 University Of Florida Method and composition for treatment of inflammatory bowel disease
CA2344913A1 (en) * 1998-09-21 2000-03-30 University Of Florida Research Foundation, Inc. Antimalarial agents
EP1488791A3 (en) * 1998-09-21 2005-04-06 University Of Florida Research Foundation, Inc. Antimalarial agents
WO2001045696A1 (en) 1999-12-21 2001-06-28 University Of Florida Research Foundation, Inc. N,n'-bis(2-hydroxybenzyl)ethylenediamine-n,n'-diacetic acid in iron chelating therapy
US6689788B1 (en) * 2000-08-25 2004-02-10 University Of Florida Method and composition for treatment of inflammatory bowel disease
EP1506162B1 (en) 2002-05-15 2008-11-26 Genzyme Corporation Synthesis of benzonitriles and benzimidates
US20040044220A1 (en) * 2002-08-22 2004-03-04 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
AU2003263948A1 (en) * 2002-08-22 2004-03-11 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
AU2003267245C1 (en) 2002-09-20 2008-05-29 Promega Corporation Luminescence-based methods and probes for measuring cytochrome P450 activity
AU2003270473A1 (en) * 2003-09-09 2005-04-27 University Of Florida Desferrithiocin derivatives and their use as iron chelators
DK1866296T3 (en) 2005-04-04 2017-02-13 Univ Florida DESFERRITHIOCINPOLYETHER-ANALOGS
US7951550B2 (en) 2005-05-31 2011-05-31 Promega Corporation Luminogenic and fluorogenic compounds and methods to detect molecules or conditions
WO2008115433A1 (en) * 2007-03-15 2008-09-25 University Of Florida Desferrithiocin polyether analogues
JP5597200B2 (ja) 2008-08-18 2014-10-01 プロメガ コーポレイション ルミネッセンスを生じる化合物およびチトクロムｐ４５０３ａ酵素を検出するための方法
BR112012001761A2 (pt) * 2009-07-27 2017-05-09 Ferrokin Bioscience Inc composto de formula i, composto farmacêutica e método de tratamento de uma condição mediada por metal em um indivduo
US20140343110A1 (en) 2011-12-16 2014-11-20 University Of Florida Research Foundation, Inc. Uses of 4'-desferrithiocin analogs
AU2014352780A1 (en) 2013-11-22 2016-06-09 University Of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof
US9790537B2 (en) 2014-01-29 2017-10-17 Promega Corporation Quinone-masked probes as labeling reagents for cell uptake measurements
WO2016176343A1 (en) 2015-04-27 2016-11-03 University Of Florida Research Foundation, Incorporated Metabolically programmed metal chelators and uses thereof
BR112020024261B8 (pt) 2018-05-29 2022-05-17 Cersci Therapeutics Inc Composto de fórmula (ia) e composição farmacêutica
WO2020231496A1 (en) 2019-05-10 2020-11-19 Cersci Therapeutics, Inc. Manufacturing methods and polymorphs of a thiazoline anti-hyperalgesic agent

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1137529A (en) * 1967-05-04 1968-12-27 Wyeth John & Brother Ltd Thiazole compositions
GB1262292A (en) * 1968-04-09 1972-02-02 Wyeth John & Brother Ltd Novel thiazoline derivatives, the preparation thereof and compositions containing the same
DE3002989A1 (de) * 1980-01-29 1981-07-30 Hoechst Ag, 6000 Frankfurt Hydroxyphenyl-thiazol, -thiazolin und -thiazolidin-carbonsaeuren, verfahren zu ihrer herstellung und ihre verwendung zur beeinflussung des kollagenstoffwechsels
DE3170401D1 (en) * 1980-07-28 1985-06-13 Ciba Geigy Ag Triazoline derivatives and processes for their preparation
US5393777A (en) * 1990-11-15 1995-02-28 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Deferration using anguibactin siderophore
AU5602594A (en) * 1992-11-16 1994-06-08 University Of Florida Research Foundation, Inc. 2-(pyrid-2'-yl)-2-thiazoline-4(s)-carboxylic acid derivatives

Also Published As

Publication number Publication date
EP0900209A4 (en) 2001-09-19
WO1997036885A1 (en) 1997-10-09
EP0900209A1 (en) 1999-03-10
JP2000505086A (ja) 2000-04-25
US5840739A (en) 1998-11-24
KR20000005100A (ko) 2000-01-25
AU2541097A (en) 1997-10-22
DE69739670D1 (de) 2009-12-31
ATE449088T1 (de) 2009-12-15
PL329172A1 (en) 1999-03-15
EP2096112A3 (en) 2009-09-09
EP1380577A1 (en) 2004-01-14
NZ332049A (en) 2001-04-27
EP2096112A2 (en) 2009-09-02
CA2250243C (en) 2002-10-08
JP3800559B2 (ja) 2006-07-26
NO315608B1 (no) 2003-09-29
JP2006152004A (ja) 2006-06-15
NO984508D0 (no) 1998-09-28
NO984508L (no) 1998-11-23
NZ509967A (en) 2005-06-24
AU715889B2 (en) 2000-02-10
EP1380577B1 (en) 2009-11-18
CA2250243A1 (en) 1997-10-09

Similar Documents

Publication Publication Date Title
BR9708460A (pt) Composto, composição farmacêutica e processo para prevenir ou tratar uma condição patológica em um humano ou animal não-humano.
HK1040198A1 (zh) 用於預防和治療內髒痛的加巴噴丁衍生物
BR9809115A (pt) Métodos para tratar inflamação e doenças inflamatórias usando inibidores de padprt
BR9806989A (pt) Processo para tratar a epiderme ou membrana da mucosa de um indivìduo mamìfero.
ES2038609T3 (es) 4,5-dihidroisoxazol, 3,5 disustituido como inhibidores de transglutaminasa.
DK0413528T3 (da) Amphotere præparater og polymere former af alphahydroxysyrer og deres terapeutiske anvendelse
BR9913833A (pt) Método para tratar diabetes, empregando em inibidor de ap2 e combinação
FI972580A0 (fi) Valmisteita ja menetelmiä ihoärsytyksen vähentämiseksi
RU94031102A (ru) Сульфамиды в качестве антагонистов эндотелина и способ лечения соответствующих заболеваний
BR9507506A (pt) Processo para exterminar uma célula processo para tratamento de càncer composição e kit terapéutico
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
FI925787A0 (fi) Proteolytiska enzymers sackarinderivatinhibitorer
BR9810146A (pt) Composto, processo para preparação do mesmo, composição farmacêutica e método para tratar ou prevenir doenças mediadas pela taquicinina
DE69029100D1 (de) Verwendung von Ketoconazol und ein Retinoid zur Behandlung der Akne vulgaris
KR920700634A (ko) 좌창 또는 건선 피부병을 치료하는 방법 및 여기에 사용되는 조성물
DE69512589D1 (de) Behandlung von durch Talgdrüse verursachten Erkrankungen mit Inhibitoren der Acyl CoA Cholesterin Acyltransferase
ATE160561T1 (de) L-carnitin-salz, dieses enthaltende kosmetische und pharmazeutische zusammensetzungen zur behandlung von dermatosen
NO166939C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive carboxylsyrederivater.
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
AU3331889A (en) 4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases
BRPI0410654A (pt) composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto
ATE251631T1 (de) Dipohosphonsäuresalze für die behandlung von osteoporose
DE69419954D1 (de) Arzneimittel zur Behandlung von Hauterkrankungen
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
DE68907386D1 (de) Verwendung von phytinsaeure oder deren salzen zur verhinderung oder behandlung von lebererkrankungen.

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]